17AAG: Low target binding affinity and potent cell activity - Finding an explanation

Molecular Cancer Therapeutics

Volumn 2, Issue 2, 2003, Pages 123-129

  Chiosis, Gabriela ^a   Huezo, Henri ^a   Rosen, Neal ^a   Mimnaugh, Edward ^b   Whitesell, Luke ^c   Neckers, Len ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; BENZOQUINONE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; PROTEIN SERINE THREONINE KINASE; QUINONE DERIVATIVE; RIFABUTIN;

ARTICLE; BINDING SITE; BREAST TUMOR; CELL CULTURE; CELL DIVISION; CELL FRACTIONATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HUMAN; MALE; MASS SPECTROMETRY; METABOLISM; PROSTATE TUMOR;

ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; BINDING SITES; BREAST NEOPLASMS; CELL DIVISION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MASS SPECTROMETRY; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; QUINONES; RIFABUTIN; SUBCELLULAR FRACTIONS; TUMOR CELLS, CULTURED;

EID: 0042855994     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Uehara, Y., Hori, M., Takeuchi, T., and Umezawa, H. Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase. Jpn. J. Cancer Res., 76: 672-675, 1985. (Pubitemid 15232451)
2. Murakami, Y., Mizuno, S., Hori, M., and Uehara, Y. Reversal of transformed phenotypes by herbimycin A in src oncogene expressed rat fibroblasts. Cancer Res., 48: 1587-1590, 1988. (Pubitemid 18091212)
3. Neckers, L., Schulte, T. W., and Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Investig. New Drugs, 17: 361-373, 1999. (Pubitemid 30135903)
4. Schulte, T. W., and Neckers, L. M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to Hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol., 42: 273-279, 1998. (Pubitemid 28393843)
5. Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G., and Workman, P. D. T-diaphorase expression and tumor cell sensitivity to 17-allyamino-17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (Bethesda), 91: 1940-1949, 1999.
6. Uehara, Y., Fukazawa, H., Murakami, Y., and Mizuno, S. Irreversible inhibition of v-src tyrosine kinase activity by herbimycin A and its abrogation by sulfhydryl compounds. Biochem. Biophys. Res. Commun., 163: 803-809, 1989. (Pubitemid 19236921)
7. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., and Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
8. Blagosklonny, M. V., Toretsky, J., and Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene, 11: 933-939, 1995.
9. Dasgupta, G., and Momand, J. Geldanamycin prevents nuclear translocation of mutant p53. Exp. Cell Res., 237: 29-37, 1997. (Pubitemid 27528025)
10. Whitesell, L., Sutphin, P. D., Pulcini, E. J., Martinez, J. D., and Cook, P. H. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol. Cell. Biol., 18: 1517-1524, 1998. (Pubitemid 28100917)
11. An, W. G., Schulte, T. W., and Neckers, L. M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ., 1: 355-360, 2000. (Pubitemid 30619563)
12. Srethapakdi, M., Liu, F., Tavorath, R., and Rosen, N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res., 60: 3940-3946, 2000. (Pubitemid 32204590)
13. Munster, P. N., Srethapakdi, M., Moasser, M. M., and Rosen, N. Inhibition of Hsp90 function by ansamycins causes morphological and functional differentiation of breast cancer cells. Cancer Res., 61: 2945-2952, 2001. (Pubitemid 32691939)
14. Hostein, I., Robertson, D., DiStefano, F., Workman, P., and Clarke, P. A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res., 61: 4003-4009, 2001. (Pubitemid 32720963)
15. Supko, J. G., Hickman, R. L., Grever, M. R., and Malspeis, L. Preclinical pharmacological evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol., 36: 305-315, 1995.
16. Stebbins, C. E., Russo, A. A., Schneider, C., Rosen, N., Hartl, F. U., and Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89: 239-250, 1997. (Pubitemid 27199896)
17. Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell, 90: 65-75, 1997. (Pubitemid 28009419)
18. Obermann, W. M., Sondermann, H., Russo, A. A., Pavletich, N. P., and Hartl, F. U. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J. Cell Biol., 143: 901-910, 1998. (Pubitemid 28547391)
19. Prodromou, C., Panaretou, B., Chohan, S., Siligardi, G., O'Brien, R., Ladbury, J. E., Roe, S. M., Piper, P. W., and Pearl, L. H. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J., 19: 4383-4392, 2000. (Pubitemid 30623749)
20. An, W. G., Schnur, R. C., Neckers, L., and Blagosklonny, M. V. Depletion of p185erbB2, Raf-1, and mutant p53 proteins by geldanamycin derivatives correlates with antiproliferative activity. Cancer Chemother. Pharmacol., 40: 60-64, 1997. (Pubitemid 27160962)
21. Scheibel, T., and Buchner, J. The Hsp90 complex: a super-chaperone machine as a novel drug target. Biochem. Pharmacol., 56: 675-682, 1998. (Pubitemid 28454577)
22. Buchner, J. Hsp90 & Co.: a holding for folding. Trends Biochem. Sci., 4: 136-141, 1999.
23. Toft, O. D. Recent advances in the study of hsp90 structure and mechanism of action. Trends Endocrinol. Metab., 9: 238-243, 1998.
24. Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med., 8: S55-S61, 2002. (Pubitemid 34297080)
25. Workman, P., and Maloney, A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert. Opin. Biol. Ther., 2: 3-24, 2002. (Pubitemid 34462457)
26. Panaretou, B., Prodromou, C., Roe, S. M., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. ATP binding and hydrolysis are essential to the function of the Hsp90 molecular chaperone in vivo. EMBO J., 17: 4829-4836, 1998. (Pubitemid 28377183)
27. Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem., 42: 260-266, 1999. (Pubitemid 29069861)
28. Chiosis, G., Rosen, N., and Sepp-Lorenzino, L. LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family. Bioorg. Med. Chem. Lett., 11: 909-913, 2001. (Pubitemid 32226213)
29. Chiosis, G., Timaul, M. N., Lucas, B., Munster, M. N., Zheng, F. F., Sepp-Lorenzino, L., and Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol., 8: 289-299, 2001. (Pubitemid 32296118)
30. Lucas, B., Rosen, N., and Chiosis, G. Facile synthesis of 9-Alkyl-8-benzyl-9H-purin-6-ylamine derivatives. J. Comb. Chem., 3: 518-520, 2001.
31. Chiosis, G., Huezo, H., Lucas, B., and Rosen, N. development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem., 10: 3555-3564, 2002.
32. Holford, J., Sharp, S. Y., Murrer, B. A., Abrams, M., and Kelland, L. R. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer, 77: 366-373, 1998. (Pubitemid 28044038)
33. DeBoer, C., Meulman, P. A., Wnuk, R. J., and Peterson, P. D. Geldanamycin, a new antibiotic. J. Antibiot. (Tokyo), 23: 442-447, 1970.
34. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem., 50: 76-85, 1985. (Pubitemid 16258399)
35. Solit, D. B., Zheng, F. F., Drobnjak, M., Munster, P. N., Higgins, B., Verbel, D., Heller, G., Tong, W., Cardon-Cordo, C., Agus, D. B., Scher, H. I., and Rosen, N. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin. Cancer Res., 8: 986-993, 2002. (Pubitemid 34517631)
36. Egorin, M. J., Sentz, D. L., Zuhowski, E. G., Dobson, J. M., Schulte, T. W., Neckers, L. M., and Eiseman, J. L. PC3 human prostate xenograft retention of, and oncoprotein modulation by, 17-allylamino-geldanamycin (17-AAG) in vivo. Proc. Am. Assoc. Cancer Res., 40: 3409, 1999.
37. Agnew, E. B., Wilson, R. H., Morrison, G., Neckers, L. M., Takimoto, C. H., and Grem, J. L. Clinical pharmacokinetics of 17-(allylamino)-17- demethoxygeldanamycin and the active metabolite 17-(amino)-17- demethoxygeldanamycin given as a one-hour infusion daily for 5 days. Proc. Am. Assoc. Cancer Res., 43: 1349, 2002.
38. Wilson, R. H., Takimoto, C. H., Agnew, E. B., Morrison, G., Grollman, F., Thomas, R. R., Saif, M. W., Allegra, C., Grochow, L., Szabo, E., Hamilton, J. M., Monahan, B. P., Neckers, L., and Grem, J. L. Phase I pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 20: 82a, 2001.
39. Munster, P. N., Tong, W., Schwartz, L., Larson, S., Kenneson, K., De La Cruz, A., Rosen, N., and Scher, H. Phase I trial of 17-(allylamino)-17- demethoxygeldanamycin (17-AAG) in patients (Pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol., 20: 83a, 2001.
40. Banerji, U., O'Donnell, A., Scurr, M., Benson, C., Brock, C., Hanwell, J., Stapleton, S., Raynaud, F., Simmons, L., Turner, A., Walton, M., Workman, P., and Judson, I. A pharmacokinetically (PK)-pharmacodynamically (PD) driven Phase I trial of the HSP90 molecular chaperone inhibitor 17-allyamino 17-demethoxygeldanamycin (17AAG). Proc. Am. Assoc. Cancer Res., 43: 1352, 2002.
41. Banerji, U., O'Donnell, A., Scurr, M., Benson, C., Hanwell, J., Clark, S., Raynaud, F., Turner, A., Walton, M., Workman, P., and Judson, I. Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino 17-demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints. Proc. Am. Soc. Clin. Oncol., 20: 82a, 2001.
42. Basso, A. D., Solit, D. B., Munster, P. N., and Rosen, N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 21: 1159-1166, 2002. (Pubitemid 34185232)
43. Naoe, T., Kiyoe, H., Yamamoto, Y., Minami, Y., Yamamoto, K., Ueda, R., and Saito, H. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy. Cancer Chemother. Pharmacol., 48: S27-S30, 2001. (Pubitemid 33738368)
44. Bagatell, R., Khan, O., Paine-Murrieta, G., Taylor, C. W., Akinaga, S., and Whitesell, L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin. Cancer Res., 7: 2076-2084, 2001. (Pubitemid 32994847)
45. Egorin, M. J., Zuhowski, E. G., Rosen, D. M., Sentz, D. L., Covey, J. M., and Eiseman, J. L. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother. Pharmacol., 47: 291-302, 2001. (Pubitemid 32640768)
46. Strik, H. M., Weller, M., Frank, B., Hermisson, M., Deininger, M. H., Dichgans, J., and Meyermann, R. Heat shock protein expression in human gliomas. Anticancer Res., 20: 4457-4462, 2000. (Pubitemid 32141803)
47. Cardillo, M. R., Sale, P., and Di Silverio, F. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res., 20: 4579-4583, 2000. (Pubitemid 32141822)
48. Xu, X., Zhao, and M., Shi, Y. Expression of heat shock proteins in laryngeal carcinoma. Zhonghua Er Bi Yan Hou Ke Za Zhi, 33: 232-234, 1998.
49. Vanmuylder, N., Evrard, L., Daelemans, P., Van Reck, J., and Dourov, N. Expression of heat shock proteins in salivary gland tumors. Immunohistochemical study of HSP27, HSP70, HSP90, and HSP110: apropos of 50 cases. Ann. Pathol., 20: 188-189, 2000.
50. Yufu, Y., Nishimura, J., and Nawata, H. High constitutive expression of heat shock protein 90 α in human acute leukemia cells. Leuk. Res., 16: 597-605, 1992.
51. Kowalski, R. J., Giannakakou, P., and Hamel, E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol). J. Biol. Chem., 272: 2534-2541, 1997. (Pubitemid 27058547)
52. Jordan, M. A., Wendell, K., Gardiner, S., Derry, W. B., Copp, H., and Wilson, L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res., 56: 816-825, 1996. (Pubitemid 26055472)
53. Lichtner, R. B., Rotgeri, A., Bunte, T., Buchmann, B., Hoffmann, J., Schwede, W., Skuballa, W., and Klar, U. Subcellular distribution of epothilones in human tumor cells. Proc. Natl. Acad. Sci. USA, 98: 11743-11748, 2001. (Pubitemid 32928799) Health